Analyst Price Targets — MLTX
Latest News for MLTX
CEO Jorge Santos da Silva sold 150,000 shares for a transaction value of approximately ~$2.75 million, based on a weighted average sale price of $18.35 per share. The sale represented 4.9% of Mr.
MoonLake Immunotherapeutics (NASDAQ: MLTX - Get Free Report) CEO Da Silva Jorge Santos sold 98,127 shares of the firm's stock in a transaction on Friday, April 10th. The shares were sold at an average price of $18.41, for a total transaction of $1,806,518.07. Following the completion of the transaction, the chief executive officer directly owned 2,976,766
MoonLake Immunotherapeutics (NASDAQ: MLTX - Get Free Report)'s share price traded down 6% during mid-day trading on Friday. The company traded as low as $18.36 and last traded at $18.2540. 326,345 shares were traded during trading, a decline of 83% from the average session volume of 1,947,956 shares. The stock had previously closed at $19.41.
BVF sold 3,750,000 shares for a transaction value of approximately $62.96 million on April 2, 2026. The sale represented 78.30% of BVF's direct holdings, reducing direct ownership to 1,039,238 shares.
ZUG, Switzerland, March 28, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (MoonLake or the Company), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announces long-term Week 40 results of the Phase 3 VELA-1 and VELA-2 clinical trials of its registrational global program in patients with moderate-to-severe HS and confirms the presentation of the…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MLTX.
U.S. House Trading
No House trades found for MLTX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.